Diabetes and cardiovascular disease

Annual Review of Medicine

Volumn 53, Issue , 2002, Pages 245-267

  Resnick, Helaine E ^a   Howard, Barbara V ^a  

^a MEDSTAR RESEARCH INSTITUTE   (United States)

Author keywords

Epidemiology; Glycosylation end products; Inflammation; Insulin resistance; Sex

Indexed keywords

ADVANCED GLYCATION END PRODUCT;

AUTONOMIC DYSFUNCTION; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CHRONIC INFLAMMATION; DIABETES MELLITUS; DIET; DISEASE ASSOCIATION; EXERCISE; GENETIC SUSCEPTIBILITY; HUMAN; HYPERTENSION; LIPOPROTEIN METABOLISM; PREVALENCE; PRIORITY JOURNAL; REVIEW; RISK ASSESSMENT; RISK FACTOR; SEX DIFFERENCE; SLEEP APNEA SYNDROME; SMOKING;

CARDIOVASCULAR DISEASES; COMORBIDITY; CORONARY DISEASE; DIABETES MELLITUS; DIABETES MELLITUS, TYPE 2; HUMANS; INSULIN RESISTANCE; RISK FACTORS;

EID: 0036178107     PISSN: 00664219     EISSN: None     Source Type: Book Series    
DOI: 10.1146/annurev.med.53.082901.103904     Document Type: Review

References (159)

1. Diabetes and atherosclerosis: An epidemologic view
2. Economic consequences of diabetes mellitus in the U.S. in 1997
3. Heart disease and diabetes
4. Resting electrocardiographic abnormalities suggestive of asymptomatic ischemic heart disease associated with non-insulin-dependent diabetes mellitus in a defined population
5. Prevalence of coronary heart disease in subject with normal and impaired glucose tolerance and non-insulin-dependent diabetes mellitus in a biethnic Colorado population. The San Luis Valley Diabetes Study
6. Myocardial infarction in Mexican-Americans and non-Hispanic whites: The San Antonio Heart Study
7. Prevalence of complications among second generation Japanese-American men with diabetes, impaired glucose tolerance, or normal glucose tolerance
8. Glucose intolerance and diabetic complications among Japanese-American women
9. Adverse effects of diabetes on multiple cardiovascular disease risk factors in women
10. Cardiovascular disease risk factors prior to the diagnosis of impaired glucose tolerance and non-insulin-dependent diabetes mellitus in a community of older adults
11. Is hyperglycemia associated with cardiovascular disease? The Framingham Study
12. A prospective study of maturity-onset diabetes mellitus and risk of coronary heart disease and stroke in women
13. Why is diabetes mellitus a stronger risk factor for fatal ischemic heart disease in women than in men? The Rancho Bernardo Study
14. Risk factors for coronary heart disease among older men and women: A prospective study of community-dwelling elderly
15. Mortality among diabetics in a national sample
16. LDL cholesterol as a strong predictor of coronary heart disease in diabetic individuals with insulin resistance and low LDL: The Strong Heart Study
17. Rising tide of cardiovascular disease in American Indians: The Strong Heart Study
18. Morbidity and mortality in diabetics in the Framingham population. Sixteen-year follow-up study
19. Predictors of 10-year macrovascular and overall mortality in patients with NIDDM: The Munich General Practitioner Project
20. Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction
21. The epidemiology of cardiovascular disease in type 2 diabetes mellitus: How sweet it is . . . or is it?
22. Prevalence and clinical implications of American Diabetes Associationdefined diabetes and other categories of glucose dysregulation in older adults: The Health, Aging, and Body Composition Study
23. Insulin resistance and obesity: The role of fat distribution pattern
24. Body fat distribution and hyperinsulinemia as risk factors for diabetes and cardiovascular disease
25. Role of deep abdominal fat in the association between regional adipose tissue distribution and glucose tolerance in obese women
26. Obesity and body fat distribution in relation to the incidence of non-insulin dependent diabetes mellitus
27. Insulin sensitivity and abdominal obesity in African-American, Hispanic and non-Hispanic white men and women: The Insulin Resistance and Atherosclerosis Study
28. Do upper-body and centralized adiposity measure different aspects of regional body-fat distribution?
29. Association of waist circumference with risk of hypertension and type 2 diabetes in Nigerians, Jamaicans, and African-Americans
30. Metabolic syndrome and ischemic heart disease in elderly men and women
31. Smoking and diabetes
32. Risk factors for mortality from all causes and from coronary heart disease among persons with diabetes: Findings from the National Health and Nutrition Examination Survey I Epidemiologic Follow-up Study
33. Smoking and diabetic microangiopathy
34. A study of patients with diabetes mellitus (type 1) and endstage renal failure: Tobacco usage may increase risk of nephropathy and death
35. Prevalence and risk factors of diabetic retinopathy in non-Hispanic whites and Hispanics with NIDDM. San Luis Valley Diabetes Study
36. American Diabetes Association: Smoking and diabetes
37. Leisuretime physical activity patterns in the U.S. diabetic population. Findings from the 1990 National Health Interview Survey - Health promotion and disease prevention supplement
38. Cardiorespiratory fitness, glycemic status, and mortality risk in men
39. Diabetes mellitus and exercise
40. Nutrition recommendations and principles for people with diabetes mellitus
41. Global estimates for prevalence of diabetes mellitus and impaired glucose tolerance in adults
42. Predictors of progression from impaired glucose tolerance to NIDDM. An analysis of six prospective studies
43. Sex differences in African-Americans regarding sensitivity to insulin's glucoregulatory and antilipolytic actions
44. Epidemiological correlates of NIDDM in Hispanics, whites and blacks in the U.S. population
45. Differential effects of BMI on diabetes risk among black and white Americans
46. Diabetes and glucose tolerance as risk factors for cardiovascular disease: The Framingham Study
47. Risk factors that attenuate the female coronary disease advantage
48. Sex differences in coronary mortality among diabetics in Evans County, Georgia
49. Relationship of clinical diabetes and asymptomatic hyperglycemia to risk of coronary heart disease mortality in men and women
50. Risk factors for coronary heart disease mortality among persons with diabetes
51. Mortality among type 2 diabetic individuals and associated risk factors: The Three City Study
52. International variation in mortality among diabetic patients: The WHO Multinational Study of Vascular Disease in Diabetics
53. Postmenopausal estrogen use, cigarette smoking, and cardiovascular morbidity in women over 50. The Framingham Study
54. Association of hyperestrogenemia and coronary heart disease in men in the Framingham cohort
55. American Diabetes Association diabetes diagnostic criteria, advancing age, and cardiovascular disease risk factor profiles: Results from the Third National Health and Nutrition Examination Survey
56. Greater effect of diabetes on LDL size in women than in men
57. Variations in oxidative susceptibility among six low density lipoprotein subfractions of differing density and particle size
58. Substantial differences in the diagnostic criteria used by diabetes experts
59. Standardization of definition, classification, and reporting in diabetes-related epidemiologic studies
60. Classification and diagnosis of diabetes mellitus and other categories of glucose intolerance
61. Report of the Expert Committee on the diagnosis and classification of diabetes mellitus
62. Prevalence of undiagnosed diabetes in three American Indian populations. A comparison of the 1997 American Diabetes Association diagnostic criteria and the 1985 World Health Organization diagnostic criteria: The strong heart study
63. When is diabetes diabetes?
64. New diabetes diagnostic criteria result in fewer cases in older adults
65. New diabetes diagnostic criteria for diabetes and mortality in older adults
66. Plasma glucose and prediction of microvascular disease and mortality: Evaluation of 1997 American Diabetes Association and 1999 World Health Organization criteria for diagnosis of diabetes
67. Comparison of ADA and WHO screening methods for diabetes mellitus in obese patients
68. Comparison of the current WHO and new ADA criteria for the diagnosis of diabetes mellitus in three ethnic groups in the UK
69. New diagnostic criteria and classification of diabetes - Again?
70. Screening for diabetes: What are we really doing?
71. The 1997 American Diabetes Association criteria versus the 1985 World Health Organization criteria for the diagnosis of abnormal glucose tolerance: Poor agreement in the Hoom Study
72. Diabetes in older adults: Comparison of 1997 American Diabetes Association classification of diabetes mellitus with 1985 WHO classification
73. Aging and diabetes
74. Isolated post-challenge hyperglycaemia confirmed as a risk factor for mortality
75. Isolated postchallenge hyperglycemia and the risk of fatal cardiovascular disease in older women and men: The Rancho Bernardo Study
76. Cardiovascular disease in older adults with glucose disorders: Comparison of American Diabetes Association criteria for diabetes mellitus with WHO criteria
77. Comparison of ADA and WHO diagnostic criteria for predicting CHD risk: The strong heart study
78. Relationship between fasting plasma glucose and glycosylated hemoglobin. Potential for false-positive diagnosis of type 2 diabetes using new diagnostic criteria
79. The postprandial state and the risk of atherosclerosis
80. Clustering of procoagulation, inflammation and fibrinolysis variables with metabolic factors in insulin resistance syndrome
81. NIDDM as a disease of the innate immune system: Association of acute-phase reactants and interleukin-6 with metabolic syndrome X
82. Relation of serum cytokine concentrations to cardiovascular risk factors and coronary heart disease
83. C-reactive protein in healthy subjects - Association with obesity, insulin resistance and endothelial dysfunction
84. Elevated C-reactive protein levels in overweight and obese adults
85. Body mass index, diabetes, and C-reactive protein among U.S. adults
86. Serum C-reactive protein and fibrinogen concentrations and self-reported angina pectoris and myocardial infarction: Findings from National Health and Examination Survey III
87. Serum C-reactive protein and self-reported stroke: Findings from the Third National Health and Nutrition Examination Survey
88. Cardiovascular disease, interleukin-6 and risk of mortality in older women: The Women's Health and Aging Study
89. The relation of markers of inflammation to the development of glucose disorders in the elderly: The Cardiovascular Health Study
90. Markers of inflammation and prediction of diabetes mellitus in adults (Atherosclerosis Risk in Communities study): A cohort study
91. Inflammation, aspirin and the risk of cardiovascular disease in apparently healthy men
92. von Willebrand factor, C-reactive protein, and 5-year mortality in diabetic and nondiabetic subjects: The Hoorn Study
93. C-reactive protein is a strong but nonspecific risk factor of fatal stroke in elderly persons
94. Relation of C-reactive protein and coronary heart disease in the MRFIT nested case-control study. Multiple risk factor intervention trial
95. C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women
96. Markers of myocardial damage and inflammation in relation to long-term mortality in unstable coronary artery disease. FRISC study group. Fragmin during instability in coronary artery disease
97. The pathophysiologic roles of interleukin-6 in human disease
98. Advanced glycosylation end products in tissue and the biochemical basis of diabetic complications
99. Advanced glycation end-products and atherosclerosis
100. Glycation of skin collagen in type I diabetes mellitus. Correlation with long-term complications
101. Nonenzymatic glycosylation and the pathogenesis of diabetic complications
102. Relation between complications of type I diabetes mellitus and collagen-linked fluorescence
103. Immunohistochemical distribution and subcellular localization of three distinct specific molecular structures of advanced glycation end products in human tissues
104. Immunohistochemical localization of different epitopes of advanced glycation end products in human athersclerotic lesions
105. Nonenzymatic glycosylation products on collagen covalently trip low-density lipoprotein
106. Advanced glycation endproducts interacting with their endothelial receptor induce expression of vascular cell adhesion molecule-1 (VCAM- 1) in cultured human endothelial cells and in mice. A potential mechanism for the accelerated vasculopathy of diabetes
107. What's the RAGE? The receptor for advanced glycation end products (RAGE) and the dark side of glucose
108. Elevated plasma levels of vascular cell adhesion molecule-1 (VCAM-1) in diabetic patients with microalbuminuria: A marker of vascular dysfunction and progressive vascular disease
109. Suppression of accelerated diabetic atherosclerosis by the soluble receptor for advanced glycation endproducts
110. Cachectin/TNF and IL-1 induced by glucose-modified proteins: Role in normal tissue remodeling
111. The effect of glucose and advanced glycosylation end products on IL-6 production by human monocytes
112. Standardizing the immunological measurement of advanced glycation endproducts using normal human serum
113. Increased serum levels of advanced glycation end products (AGEs) in children and adolescents with IDDM
114. Tobacco smoke is a source of toxic reactive glycation products
115. Advanced glycation endproducts and cigarette smoking
116. Snoring and cerebral infarction
117. Snoring as a risk factor for hypertension and angina pectoris
118. Association of sleep disordered breathing, sleep apnea, and hypertension in a large community-based study. Sleep Heart Health Study
119. Cardiovascular risk factors in patients with obstructive sleep apnoea syndrome
120. Associations of symptoms of sleep apnea with cardiovascular disease, cognitive impairment, and mortality among older Japanese-American men
121. Factors predicting sleep disruption in Type II diabetes
122. Diabetes and sleep apnea
123. Cardiovascular autonomic neuropathy: Clinical manifestations and measurement
124. Mortality in diabetic patients with cardiovascular autonomic neuropathy
125. Obstructive sleep apnoea and diabetes mellitus: The role of cardiovascular autonomic neuropathy
126. Cardiorespiratory arrest and diabetic autonomic neuropathy
127. Sleep apnoea in diabetic patients with autonomic neuropathy
128. Nocturnal oxygen desaturation in diabetic patients with severe autonomic neuropathy
129. Impaired hypoxic ventilatory drive in diabetic patients with autonomic neuropathy
130. Impact of sleep debt on metabolic and endocrine function
131. The Sleep Heart Health Study: Design rationale and methods
132. Haptoglobin phenotype and vascular complications in patients with diabetes
133. Haptoglobin genotype as a risk factor for diabetic retinopathy
134. Haptoglobin phenotype and diabetic nephropathy
135. Epidemiology of the pleurimetabolic syndrome
136. Coronary heart disease incidence in NIDDM patients in the Helsinki Heart Study
137. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: Results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study
138. Cardiovascular events and their reduction with pravastatin in diabetic and glucose-intolerant myocardial infarction survivors with average cholesterol levels
139. Cholesterol lowering with simvastatin improves prognosis of diabetic patients with coronary heart disease. A subgroup analysis of the Scandinavian Simvastatin Survival Study (4S)
140. Effect of fenofibrate on progression of artery disease in type 2 diabetes: The Diabetes Atherosclerosis Intervention Study, a randomised study
141. Evaluation treatment of high blood cholesterol in adults. Executive summary of the Third Report of the National Cholesterol Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III)
142. The effect of aggressive lowering of low-density lipoprotein cholesterol levels and low-dose anticoagulation on obstructive changes in saphenous-vein coronary-artery bypass grafts
143. Aggressive lipid-lowering therapy compared with angioplasty in stable coronary artery disease
144. Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction
145. Effects of intensive blood pressure lowering and low-dose aspirin in patients with hypertension: Principal results of the Hypertension Optimal Treatment (HOT) randomized trial
146. Distribution and multiple regression analysis of blood pressure in 10,000 Israeli men
147. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33)
148. Effects of ramipril on cardiovascular and microvascular outcomes in people With diabetes mellitus: Results of the HOPE study and Micro-HOPE substudy
149. The effect of nisoldipine as compared with analapril on cardiovascular outcomes in patients with non-insulin dependent diabetes and hypertension
150. Effect of angiotensin-converting enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: The Captopril Prevention Project (CAPP) randomized trial
151. Outcome results of the Fosinopril versus Amlodipine Cardiovascular Events Trial (FACET) in patients with hypertension and NIDDM
152. Effect of captopril on progression to clinical proteinuria in patients with insulin-dependent diabetes mellitus and microalbuminuria
153. Long-term stabilizing effect of angiotensin-converting enzyme inhibition on plasma creatinine and on proteinuria in normotensive type II diabetic patients
154. Long-term renoprotective effect of angiotensin-converting enzyme inhibition in non-insulin-dependent diabetes mellitus. A 7-year follow-up study
155. The optimal level of blood pressure and urine protein excretion for the prevention of progression of chronic renal disease